4.3 Review

Biomarkers for Helicobacter pylori infection and gastroduodenal diseases

Journal

BIOMARKERS IN MEDICINE
Volume 8, Issue 9, Pages 1127-1137

Publisher

FUTURE MEDICINE LTD
DOI: 10.2217/BMM.14.72

Keywords

antibody; biomarkers; Helicobacter pylori; miRNA

Funding

  1. NIH [DK62813]
  2. Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan [22390085, 22659087, 24406015, 24659200, 23790798]
  3. Strategic Young Researcher Overseas Visits Program for Accelerating Brain Circulation for Japan Society for the Promotion of Science (JSPS)
  4. Strategic Funds for the Promotion of Science and Technology from Japan Science and Technology Agency (JST)
  5. Grants-in-Aid for Scientific Research [26640114, 24406015, 23790798, 25293104, 25860544] Funding Source: KAKEN

Ask authors/readers for more resources

Helicobacter pylori infection is a major cause of gastric cancer. Although identifying H. pylori infected subjects is the first approach for delineating the high-risk population for gastric cancer, the presence of H. pylori antibodies is not sufficient for gastric cancer screening. Among H. pylori infected subjects, only a minority of infected individuals develop gastric cancer. Serologic markers of H. pylori infection can serve as potential predictors for the development of gastric cancer. Serum or urinary H. pylori antibodies, cytotoxin-associated gene A antibodies, pepsinogen and microRNAs were reported to be associated with precancerous lesions or gastric cancer. In this review, we summarized the utilities and limitations of each strategy.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available